Next Article in Journal
Impact of Sex and Gender on Heart Failure
Previous Article in Journal
Albrecht von Haller Awards of the Swiss Heart Foundation 2023
 
 
Cardiovascular Medicine is published by MDPI from Volume 28 Issue 1 (2025). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Editores Medicorum Helveticorum (EMH).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Breast Cancer and Cardiovascular Rsk

by
Valentina A. Rossi
1,
Anton Oseledchyk
2 and
Gabriela M. Kuster
3,4,5,*
1
University Heart Centre, University Hospital of Zurich, Zurich, Switzerland
2
Departments of Medical Oncology, University Hospital Basel, Basel, Switzerland
3
Departments of Cardiology, University Hospital Basel, Basel, Switzerland
4
Departments of Biomedicine, University Hospital Basel, Basel, Switzerland
5
University of Basel, Basel, Switzerland
*
Author to whom correspondence should be addressed.
Cardiovasc. Med. 2023, 26(3), 100; https://doi.org/10.4414/cvm.2023.02275
Submission received: 17 February 2023 / Revised: 17 March 2023 / Accepted: 17 April 2023 / Published: 17 May 2023

Abstract

With the continuous improvement of therapies against breast cancer, the long-term onset of cardiovascular disease (CVD) is becoming increasingly relevant for both cardiologists and oncologists. Not only CVD arises from known cardiac side effects of several anti-cancer therapies, but cancer itself seems to promote CVD. On the other hand, there is increasing evidence that CVDs such as myocardial infarction and heart failure predispose to future development of cancer. The fast-developing field of cardio-oncology aims to characterise cancer patients in order to implement effective tools for surveillance and prevention of cardiovascular adverse events and to raise awareness for the increased cancer incidence in patients with CVD. The aim of this review is to highlight cardiovascular side effects and toxicities of some of the most important breast cancer therapies and to provide an overview of what is known on the complex interplay between CVD and breast cancer.

The aim of this review is to highlight the cardiovascular-related adverse effects of some of the most important breast cancer therapies and to provide an overview of the common pathways influencing the complex interplay between CVD and breast cancer. The first section summarises the epidemiology and the proposed pathophysiological mechanisms behind cardiotoxicity of drugs used in breast cancer treatment, including anthracyclines, HER2-therapies, radiotherapy and hormone therapy. In the second part, correlation of cardiovascular risks and breast cancer related outcomes are discussed, with a focus on the shared risk factors between CVD and breast cancer. Finally, evidence of how CVD may influence and predispose for the development of cancer is presented.

Introduction

Due to impressive advances in cancer therapies, survival of women presenting with early breast cancer continuously improved over the past decades. The reduction in cancer-related mortality has led to a corresponding increase in cardiovascular diseases (CVD), which currently represent the leading cause of morbidity and mortality among breast cancer survivors in Western countries [1]. Besides cardiovascular side effects of anti-cancer therapies, the increase in CVD is both influenced by ageing and shared risk factors between CVD and breast cancer, such as obesity and smoking [2].
Cardiovascular side effects of breast cancer therapies are diverse and include, among others, an increased risk of heart failure associated with anthracyclines and human epidermal growth factor-receptor 2 (HER2) inhibitors, the promotion of atherogenesis associated with long-term oestrogen suppression and of coronary artery disease due to (particularly left-sided) chest radiation [2,3,4]. In addition, there is increasing evidence that CVDs such as myocardial infarction might directly promote the development of breast cancer due to complex cross-disease mechanisms involving a deranged immune answer [5].
Cardio-oncology represents a new developing branch of cardiology, which aims to make cancer treatments safer from a cardiovascular perspective. A better understanding of the pathophysiological mechanisms behind CVD and cancer will allow not only the development of more efficient tools for surveillance and prevention of cardiovascular adverse events, but also raise the awareness that patients affected by CVD might in the future present with cancer.

Cardiotoxicity of breast cancer therapies

Anthracyclines

Anthracyclines are highly effective in the treatment of various solid tumours and, as such, still represent the cornerstone of mostly neoadjuvant chemotherapeutic regimens for highrisk early breast cancer (Figure 1) [6]. Although highly effective, their use has been limited due to irreversible, dose-dependent cardiac damage, which may negatively affect the prognosis despite effective cancer treatment. Therefore, appropriate risk stratification and cardiovascular monitoring before starting as well as during anthracycline therapy are recommended to guarantee optimal clinical outcome [7].
Understanding the pathophysiological mechanisms behind anthracycline-induced cardiotoxicity is critical to develop appropriate prevention and treatment strategies. Initially, anthracyclines were believed to cause left ventricular dysfunction mainly by directly promoting oxidative stress via iron-dependent generation of reactive oxygen species (ROS) [8]. Later on, further data from animal models revealed that toxicity-related mechanisms depend on the effects of doxorubicin on the type II topoisomerase [9]. Type II topoisomerase plays an important role in DNA replication by causing transient breaks and reunion of double-stranded DNA. Through binding to type II topoisomerase, doxorubicin inhibits its activity, which leads to activation of a DNA damage response and apoptosis in fast replicating cells. However, doxorubicin-bound type II topoisomerase also suppresses the transcription of genes involved in oxidative phosphorylation and electron transport, thus directly interfering with mitochondrial biogenesis and function resulting in increased ROS generation and altered mitochondrial biogenesis in cardiomyocytes [9]. Since cardiac involvement is mainly related to the interaction between doxorubicin and type II topoisomerase, patients with higher expression of this isoform in cardiomyocytes are more likely to develop cardiotoxicity. In humans, anthracyclines have a dose-dependent toxicity. In early stages, anthracyclines may lead to reversible myocyte damage and dysfunction, mainly related to oxidative stress, so that an improvement of the left ventricular ejection fraction (LVEF) is expected once the therapy is withdrawn and heart failure therapy is started. Once myocyte death occurs, the damage becomes irreversible, leading to a dose-dependent reduction in left ventricular (LV) mass likely caused by apoptosis and myocyte atrophy [10,11]. A reduction in the LV mass index represents an adverse prognostic factor for cardiovascular outcomes [10,11].
The cumulative life-time dose of anthracyclines is conventionally limited to ≤550 mg/ m2 doxorubicin (or the calculated equivalent in case other anthracyclines are used) based on epidemiological data showing a dose-corresponding incidence of heart failure of 7% at this threshold [2]. The diagnosis of anthracycline-related cardiotoxicity relies on imaging (typically measurement of LVEF by transthoracic echocardiography and LV global longitudinal strain). Based on increased imaging sensitivity, the incidence of heart failure for the same cumulative dose is 26%, resulting in a reduction of the recommended cumulative lifetime dose to 400-450 mg/m2 (Figure 2) [12]. Although such doses are usually not reached in breast cancer patients, lower doses may cause cardiotoxicity in vulnerable patients and combination with other potentially cardiotoxic therapies, namely HER2-inhibiting drugs or chest radiation may also increase the risk of cardiovascular toxicity. Elevated troponin values before anthracycline therapy may help identify those patients, who will be at highest risk to experience late-onset cardiotoxicity [2]. Several prevention and screenings strategies have been proposed to reduce the burden of anthracycline-related cardiotoxicity while at the same time guaranteeing effective cancer treatment. Mostly, proposed strategies include administration of anthracyclines via continuous infusion, as liposome-encapsulated drugs or switching to less cardiotoxic anthracyclines such as epirubicin or idarubicin [13]. Furthermore, simultaneous use of cardio-protective drugs such as dexrazoxane, a strong topoisomerase inhibitor itself, which prevents anthracyclines from binding to the type II topoisomerase-complex, may be employed [13]. This therapy is however costly, only approved in adults with progressive solid tumours who already received >300 mg/m2 doxorubicin and might reduce anthracycline’s anti-cancer efficacy [13]. Although anthracycline-related cardiotoxicity was initially defined as irreversible, myocardial recovery after anthracycline-induced injury may occur following early therapy with enalapril and carvedilol [14]. However, studies were affected by short-term follow-ups and it remains unclear whether the positive results derive from primary cardioprotection or rather from variation in haemodynamics [13].
Screening strategies are the cornerstone to monitor anthracycline therapy. Transthoracic echocardiography with strain analyses for detection of ventricular damage prior to manifest LV dysfunction has emerged as a promising method. With this respect, cardiotoxicity is defined as the onset of symptomatic cardiac dysfunction with heart failure symptoms independently from LVEF during the course of anthracycline therapy or an asymptomatic cardiac dysfunction defined as new LVEF reduction <50% or a new relative reduction in global longitudinal strain of >15% from baseline and/ or a new rise in cardiac biomarkers (troponin or natriuretic peptide) despite a LVEF ≤50% [15,16]. Cardiac biomarkers of myocyte damage such as troponin are helpful, but their specificity is limited and the timing as well as the exact cut-off to define anthracycline-related cardiotoxicity have not been defined in large prospective trials yet [17]. However, according to the new European Society of Cardiology (ESC) guidelines, measurement before each cycle of anthracyclines is recommended [15]. Further biomarkers such as NT-proBNP may identify patients at higher risk of developing cardiotoxicity and may be more helpful for long-term surveillance [17].

Cyclophosphamide

Cyclophosphamide is an alkylating agent with cytostatic properties, which is related to the onset of cardiomyopathy when administered in high doses [18]. Cyclophosphamide is metabolised via cytochrome P450 to aldophosphamide, which decomposes to phosphoramide mustard and acrolein. The first is an active neoplastic agent which induces apoptosis by interacting with DNA, whereas the latter is a toxic metabolite which causes toxicity in the myocardium, cardio-fibroblasts and endothelial cells [19]. At a lower dose, cyclophosphamide results mainly in a therapeutic immunosuppression, whereas the cardiotoxic effect is particularly evident at an antineoplastic therapeutic dose of 120-200 mg/kg [20]. Cyclophosphamide is most commonly administered in combination with an anthracycline (doxorubicin or epirubicin) in neoadjuvant treatment of high-risk early breast cancer (Figure 1) [21,22]. Prior to recent de-escalation studies, standard treatment for all women with breast cancer included both therapies. Presently, for lower risk patients, anthracyclines are omitted and cyclophosphamide is combined with docetaxel. However, high-dose cyclophosphamide is not used as breast cancer therapy. Therefore, no routine surveillance of breast cancer patients receiving cyclophosphamide is needed.

Taxanes

Taxanes are microtubule-stabilising drugs, which act on the cellular mitotic spindles and induce cell death during mitosis [23]. In current practice, taxanes are used ubiquitously in all chemotherapy regimens for early breast cancer (Figure 1). In triple negative and HER2-positive breast cancer docetaxel three-weekly or paclitaxel weekly are combined with carboplatin. In hormone receptor positive HER2-negative breast cancer combination of taxane and cyclophosphamide is standard of care [24]. Due to the complexity of the therapeutic regimens and multidrug interactions, it is often difficult to define the exact role of taxanes alone when defining cardiotoxicity. Indeed, taxanes relevantly interact with anthracyclines and increase their plasma levels, promote the formation of more cardiotoxic metabolites and enhance the global cardiotoxicity [25,26]. Thus, particular caution is warranted when both therapies are administered together and the administration of anthracycline in separate infusions before taxanes, particularly paclitaxel, is recommended [2]. Taxanes are, however, known for their proarrhythmogenic effect as well as for inducing vasospasms in the coronary arteries (Figure 2) [15].

HER2 inhibitors

Inhibitors of HER2 such as antibodies (trastuzumab, pertuzumab), antibody-drug conjugates (trastuzumab emtansine, trastuzumab deruxtecan) or small molecule tyrosine kinase inhibitors (lapatinib, neratinib, tucatinib) are used either as monotherapy or in conjunction with chemotherapies for the treatment of HER2-positive breast cancer (Figure 1). Contrary to anthracyclines, trastuzumab-related cardiotoxicity mainly develops during treatment, is mostly reversible, not cumulative dose-related, albeit increasing with long-time use, and long-term follow-up data (up to ten years after treatment) are reassuring [2,27]. If trastuzumab was administered right after anthracycline containing regimens, a summative effect with respect to the incidence of heart failure has been observed (Figure 2) [2]. Antibodies such as trastuzumab bind to the extracellular domain of HER2 inhibiting its activity, whereas tyrosine kinase inhibitors enter the cell and target the HER2 intracellular kinase domain [28]. The aetiology behind trastuzumab-induced cardiotoxicity is mainly related to myocyte dysfunction in the absence of irreversible injury such as major cell death as shown in biopsy studies [29]. HER2 inhibitors block HER2 receptors on the surface of cardiomyocytes interfering with signalling pathways responsible for cell repair in response to cellular stress as well as with antiapoptotic pathways [29]. These effects explain the enhanced cardiotoxicity of the combination of chemotherapies with anthracyclines and HER2 inhibitors.
Since cardiotoxicity related to adjuvant HER2-blockade mainly occurs during treatment, several surveillance protocols have been developed [30]. Heart failure is the main reported side effect with high incidence rates up to 27% when administered in combination with anthracyclines in women with metastatic breast cancer, but as low as 3% when given alone [31,32]. Older age, above 50 years, a lower baseline LVEF ≤55% or presence of traditional cardiovascular risk factors are associated with an increased risk [33]. The role of troponins in the surveillance during HER2 directed therapy is questioned, since myocardial necrosis is rare and not directly caused by these drugs [17]. As no population-based studies investigating the long-term risk of cardiac dysfunction in women treated with HER2-inhibitors alone are available, there are no clear protocols for risk stratification and recommendations about preventive strategies in these patients [34]. However, a recent meta-analysis showed a beneficial effect of beta blockers, angiotensin converting enzyme inhibitors and angiotensin receptor blockers on LVEF under trastuzumab and, to a lesser extent, also anthracycline therapy [35]. In general, repeated echocardiographic and biomarker assessment for early detection of cardiotoxicity is recommended during and after treatment according to risk category and should be continued long-term, as HER2-related toxicity may increase over time [15,30].
Recently, novel antibody-drug conjugates (ADC) such as trastuzumab emtansine (TDM1) and trastuzumab deruxtecan (TDXd) entered the clinical stage. Highly potent but very toxic cytostatic agents are coupled to an antibody targeting HER2 facilitating an increase of intratumoural drug levels and a decrease of off-target toxicity. T-DXd is used as second line therapy in HER2 positive and selected HER2 “low” expressing metastatic breast cancer [36,37]. In early HER2 positive breast cancer, adjuvant treatment escalation to TDM1 is standard of care if a complete pathologic response was not achieved after neoadjuvant therapy (Figure 1) [38]. Whereas clinical experience with these kinds of drugs is still limited and only little is known about their potential cardiotoxicity, results on tumour efficacy are encouraging [37,39].

Radiation

Radiation therapy is associated with a higher long-term risk for cardiovascular adverse events and is particularly increased in case of left-sided breast radiotherapy (Figure 2) [40]. Left-sided radiotherapy might affect cardiac structures and function in several ways, from pericardial and myocardial fibrosis resulting in constriction and restriction to alteration of the valvular apparatus, a more rapid progression of coronary artery disease, up to the involvement of the heart conduction system [17]. The scope of the cardiac involvement depends on the radiation dose, the involved heart region as well as on pre-existing comorbidities and concomitant cardiotoxic therapies [2]. In particular, radiation therapy induces direct endothelial damage, which favours the onset of atherosclerotic coronary plaque formation and is related to a general increase of death from ischaemic heart disease [41,42]. Furthermore, radiation may induce fibrosis, calcification and dysfunction of the heart valves [43].
Over the past years, several strategies were developed to protect the heart, such as lowering the total radiation dose, using more precise radiation fields, the deep inspiration breath hold technique and shielding of the myocardium [34]. The application of these preventive techniques has led to a substantial decrease in the risk of cardiovascular death in women who underwent radiotherapy for breast cancer [42].

Hormone therapy

Endocrine hormonal therapy is the cornerstone of adjuvant cancer therapy in breast cancer expressing hormone-sensitive receptors (such as oestrogen or progesterone receptors, Figure 1) [44]. Hormonal therapies interfere with oestrogen-stimulated growth of normal and cancerous cells. Depending on their exact molecular target, they exhibit several cardiovascular side effects. In adjuvant settings, hormone therapies might be administered for more than five years, thus emphasising the importance of the evaluation of their cardiovascular side effect profile.
Tamoxifen represents the first-line endocrine intervention developed for early-stage hormone receptor-positive breast cancer in premenopausal women, in whom it efficiently interferes with oestrogen signalling by binding to oestrogen-receptors [45]. Although tamoxifen has lipid-lowering effects with reduction in total serum and low-density lipoprotein cholesterol, long-term clinical trials failed to demonstrate a protective effect with respect to cardiovascular outcomes [46]. On the contrary, tamoxifen has been linked to higher rates of arterial thrombotic events (Figure 2) [44].
Aromatase inhibitors (AIs) represent the principal hormonal therapy for postmenopausal women alone or in combination with gonadotropin releasing hormone (GnRH) analogues in premenopausal women with high-risk features (Figure 1) [45,47,48]. AIs inhibit the endogenous oestrogen production by acting on the aromatase enzyme, which normally converts androstenedione to oestradiol. Adjuvant therapy with AIs is efficient in both postmenopausal women, where oestrogen production occurs mainly thorough aromatase in peripheral tissues, as well as in premenopausal women [49,50]. Several trials compared cardiovascular outcomes in patients under AIs to patients treated with tamoxifen and found AIs to be associated with an increased cardiovascular risk [51,52]. In contrast, in a randomised trial of AIs versus placebo after five years of tamoxifen, no increased cardiovascular risk was found [53]. Still, AIs have been associated with a higher rate of arterial thrombosis and stroke as well as some of them with an increase in blood lipids, despite a relatively low cumulative rate of adverse events [54]. However, the quality of these trials is often limited by lack of sufficient information about cardiovascular therapies and cardiovascular-related comorbidities, which might have influenced the results. Current guidelines recommend a baseline and annual assessment of cardiovascular risk based on the SCORE2 or SCORE2-OP and secondary prevention according to the degree of dyslipidaemia and/or arterial hypertension [15].
Another promising therapy are cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which target the growth of cancer cells and are currently used to treat hormone receptor-positive HER2-negative metastatic breast cancer in association with hormone therapies [55]. Whereas QT-time prolongation has been described for ribociclib, data on long-term cardiotoxicity is not yet available [56].

Immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) consist of monoclonal antibodies, which block physiological immune brakes or “checkpoints” such as the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4: Ipilimumab, tremelimumab), programmed cell death protein 1 (PD-1: Nivolumab, cemiplimab, pembrolizumab) or its ligand (PD-L1: Atezolizumab, avelumab, durvalamab) to activate T-lymphocytes that target the tumour [15]. Triplenegative breast cancer cells overexpress PD-L1, which renders them susceptible to ICI therapies [57]. Hence, addition of pembrolizumab to chemotherapy has recently been approved for treatment of early and metastatic PD-L1 positive triple negative breast cancer (Figure 1) [58,59].
A potentially lethal side-effect of these drugs is related to the activation of T-cells that may also target other, non-cancerous tissues including the myocardium [60]. ICI-related myocarditis most frequently develops within the first twelve weeks of treatment and manifests with a wide range of signs and symptoms, ranging from asymptomatic troponin elevation to fulminant myocarditis with severe myocardial dysfunction [60,61], though the diagnosis can be challenging in milder cases (Figure 2). Endomyocardial biopsy should be undertaken in case of uncertainty, as a positive diagnosis has relevant consequences due to the necessary discontinuation of a potentially curative therapy [15]. Multidisciplinary team discussion is warranted to assess the risks versus benefits of resuming therapy in cases of mild myocarditis [15]. Treatment consists of highdose corticosteroids and, in case of a non-response, other immunosuppressive agents. Besides myocarditis, ICI can also lead to vasculitis (and therefore acute coronary syndrome) or pericarditis and rarely, Takotsubo cardiomyopathy may occur.

Cardiovascular risk and outcome of breast cancer patients

In the last decades, steady developments in cancer therapies for breast cancer have dramatically improved survival increasing deaths from other causes, including cardiovascular and cerebrovascular diseases. The diagnosis of cancer holds per se a worse prognosis in terms of cardiovascular mortality and morbidity [62]. In addition, according to an English retrospective cohort study, cardiovascular mortality “overruns” cancer mortality in >60 yearold survivors of nine different cancer types, including breast cancer [63]. According to several studies, breast cancer survivors have a 1.8-fold higher risk of cardiovascular death compared to cancer-free women in the longterm, irrespective of tumour stage, hormone receptor status or age at diagnosis and the risk is even higher in those receiving chemotherapy [64,65]. Although older patients had the highest risk, suggesting a summative effect with traditional risk factors, even breast cancer with positive oestrogen-receptor expression was linked to an increased mortality [64]. In the Women’s Health Initiative study including older breast cancer survivors a higher incidence of heart failure with preserved EF (HFpEF) as compared to heart failure with reduced EF (HFrEF) has been observed. HFpEF was related to a twelve-fold higher risk for cardiovascular mortality [66]. On the other hand, the onset of HF was related to a non-significant two-fold higher risk for breast cancer mortality [66].
The pathophysiological mechanisms underlying this association are not well understood. In the Pathways Heart Study, an ongoing prospective cohort study, 13,642 women firstly diagnosed with invasive breast cancer were compared to 68,202 controls matched for age and ethnicity with no history of breast cancer in a 5:1 fashion [67]. Patients who received combined anthracyclines and trastuzumab had the highest risk of long-term cardiovascular adverse events defined as heart failure incidence and/or cardiomyopathy as compared to both controls and patients who were treated with monotherapy [67]. Interestingly, the risk proportionally increased from the lowest elevated risk in women treated with anthracyclines without trastuzumab, followed by those on trastuzumab without anthracyclines and, in line with other cohort studies, by those with combined therapy [67,68]. Considering patients with previous traditional cardiovascular risk factors, the risk of rate of death from CVD and breast cancer is similar within the first five years after cancer diagnosis and, thereafter, death due to CVD dramatically increases reaching the highest prevalence in women 66 years or older [69]. Furthermore, anthracycline exposure has been related to a 1.8up to 3-fold higher risk for arrhythmia, although this might itself represent a phenotype of an underlying cardiomyopathy [67,69]. Accordingly, the recent SEER Medicare Analysis showed a higher incidence of atrial fibrillation in women with breast cancer as compared to women without cancer. This was associated with an increased cardiovascular mortality after one year follow-up [70]. Still, the increasingly investigated cancer therapy-related cardiotoxicity does not account alone for the enhanced cardiovascular mortality reported in large prospective epidemiological studies [67,71].

Shared risk factors

Although large-scale population-based studies investigating the risk of CVD in breast cancer survivors have been inconsistent, a recent cohort study based on medical records found that long-term breast cancer survivors had a higher risk of CVD at 10-15 years from initial diagnosis [71]. Interestingly, the risk came to the same as for the general population after >15 years from diagnosis and, in general, an association between chemotherapy, hormonal therapy or radiotherapy with late-onset CVD was not observed [71]. Main predictors for CVD in this study were older age, obesity, a family history of CVD, a family history of breast cancer, low education and comorbidities according to the Charlson Comorbidity Index [71].
Indeed, breast cancer and CVD share many common risk factors such as smoking, older age, obesity and unhealthy diet rich in red or processed meats and high-fat dairy products (Figure 3) [28]. Different types of fat seem to differently affect the risk of breast cancer. In particular, a diet rich in n-3 polyunsaturated fatty acids has been associated with a decrease in both adverse cardiovascular events and, according to a meta-analysis, with a risk reduction of breast cancer [72]. However, another study indicates that this association may be primarily driven by a lower carbohydrate intake [73]. Alcohol consumption represents an important exception: although a light to moderate alcohol consumption has been associated with a risk reduction for CVD in a J-shaped fashion [74], it is associated with a continuous dose-dependent increase in the risk for particularly hormone receptor-positive breast cancer [75]. All in all, there is conflicting evidence on the link between dietary-related risk factors and the onset of CVD and breast cancer, as these associations are mainly based upon epidemiological studies, which fail to provide causation and are largely influenced by population-related cofounders [28].
Similarly, a sedentary lifestyle has been associated with both an increased risk of CVD and breast cancer, whereas an active lifestyle has been associated with a lifetime risk reduction of breast cancer of 9-18%, with lower values in women who used hormone replacement therapy [76,77,78]. As in CVD, physical activity has a positive prognostic effect also in breast cancer survivors [79]. The pathophysiology behind this association is likely related to the effects of endogenous sex steroids and to the positive effects of physical activity on insulin sensitivity, oxidative stress, chronic inflammation and immune function [80].
Obesity, which is often strictly related to a sedentary lifestyle, is a known risk factor for CVD in a linear progressive fashion [76]. In contrast, although each 5 kg weight increase is associated with an 11% risk increase of breast cancer, this was only true for postmenopausal women, whereas no relationship was found for premenopausal women, in whom long-term obesity seems to have rather a protective effect [81]. On the other hand, short-term weight gain in the perimenopause has been associated with higher breast cancer risk, even after controlling for Body Mass Index [82].
Smoking is a well-established risk factor for CVD, however, epidemiological evidence about its role in breast cancer is inconsistent, likely due to heterogeneity in clinical studies and poor prospective studies [76,83,84]. Recently, a positive association among women who started smoking early in their adolescence has been reported [84]. In this study, Jones et al. observed a summative effect of smoking in the presence of a positive family history of breast cancer, likely linked to genetic variants in enzymes involved in metabolism of carcinogens such as N-acetyltransferase 2 [85].

When CVD promotes breast cancer

Cancer onset is favoured by adverse variation in cellular homoeostasis. However, the direct impact of CVD on breast cancer has been poorly investigated. Lately, new evidence from animal models has shed light on the influence of acute cardiovascular events such as a myocardial infarction on the development or progression of cancer. Myocardial infarction induces a local and systemic inflammatory host response by provoking myocyte necrosis [86]. After a myocardial infarction, β3-adrenergic signalling leads to the release of leukocytes and myeloid progenitor cells from the bone marrow, which regulate the local inflammatory response in the atheromatic ruptured plaque [86]. The locally activated proinflammatory mononuclear phagocytes release interleukin-1. This cytokine epigenetically reprograms myeloid cells in the bone marrow and in extramedullary sites toward an immunosuppressive state and induces systemic monocytosis. This event finally leads to deleterious cross-disease communication, enabling tumour growth (Figure 3) [86]. In fact, monocytes are among the key regulators of the tumour microenvironment and are responsible for the tumour’s immune evasion, neoangiogenesis as well as cell migration and proliferation [87]. The presence of these synergies between myocardial infarction and breast cancer was lately investigated in a mouse breast cancer model. Indeed, mice with breast cancer who experienced a myocardial infarction had higher tumoral CD45+ monocytes as compared to those with no myocardial necrosis [5]. Supporting these preclinical observations, the authors performed a retrospective analysis of patients with breast cancer and no known CVD and observed that the onset of cardiovascular events was related to an increased cancer-specific mortality of 60% [5].
The association between heart failure, particularly from an ischaemic aetiology and solid cancers (excluding non-melanoma skin cancer) has been previously described [88,89]. This risk was increased irrespective of age and sex and determined an additional risk of death in this population. The causal relationship between heart failure and cancer was firstly demonstrated in a murine model of precancerous polyps, where heart failure induction resulted in increased tumour formation and accelerated tumour growth [90].
Several proteins have been detected in heart failure patients, which might predispose to cancer development via different interconnected pathways, like fibronectin, paraoxonase 1, and coeruloplasmin. Alpha 1-antichymotrypsin (SERPINA3), an acutephase protein related to systemic inflammation and newly recognised as a marker of cellular proliferation related to colorectal metastasis, was found to be elevated in both murine heart failure models as well as in plasma of patients with heart failure providing a possible pathophysiological link between heart disease and cancer (Figure 3) [90]. Finally, evidence for a direct link between heart failure and cancer arises from the CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) trial, in which the interleukin 1β antibody canakinumab was shown to decrease the incidence of new-onset cancer [91].
Finally, there is evidence that serum levels of NT-proBNP and high-sensitivity troponin T, markers of cardiac stretch and myocardial injury were elevated in patients with cancer before the initiation of any cancer therapy [92]. Furthermore, patients with elevated NT-proBNP presented with an increased risk of developing all-cause cancer and colorectal cancer [90]. As such, subclinical myocardial damage not only could be present in patients with cancer, but also predispose to its development.

New perspective

Lately, new diagnostic tools to test for chemotherapy-related toxicity such as human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), have been developed as a platform for mechanistic toxicity studies. Such studies have already advanced our understanding of the mechanisms behind anthracycline-related cardiotoxicity and immune checkpoint inhibitor-related cardiotoxicity. Most importantly, hiPSCs pave the road to the development of personalised medicine based on patients’ peculiarity and comorbidities and might represent the future of cardio-oncology [93].

Conclusions

Recent developments in breast cancer therapy have increased efficacy and treatment success resulting in better outcomes even in advanced stages of the disease. However, most of these therapies are associated with possible cardiovascular side effects, which need to be promptly recognised and addressed by multidisciplinary teams involving both cardiologists and oncologists. Of note, also general practitioners play an important role in the long-term surveillance of these patients. They likewise should be aware of the increased cardiovascular risks that breast cancer survivors face and treat them accordingly. Similarly, general practitioners should promote breast cancer screening initiatives in all women and, particularly, in women with increased cardiovascular risk factors. The recent publication of the first ESC guidelines on cardio-oncology represents an important step forward for the management of these patients and will help raise the awareness for the cardiovascular risk of cancer patients in the medical community [15]. From a clinical point of view, this is particularly crucial for affected women, which have been historically underdiagnosed and undertreated for CVD. Furthermore, many mechanistic aspects underlying the association between cardiovascular and breast cancer risk factors and the interactions of both disease entities are incompletely understood and need to be further investigated to consequently develop adequate prevention strategies.

Disclosure statement

VAR reported no financial support and no other potential conflict of interest. AO has received support for attending the ESMO (European Society for Medical Oncology) congress 2022 from Janssen by covering his travel and hotel costs. GMK reports a research grant from the Swiss National Science Foundation (SNSF) not related to the content of the presented article. She is a board member of the Swiss Society of Cardiology and has received consulting fees and/or payments for lectures from Janssen Cilag (payment to the institution).

References

  1. Patnaik, J.L.; Byers, T.; Di Guiseppi, C.; Dabelea, D.; Denberg, T.D. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study. Breast Cancer Res. 2011, 13, R64. [Google Scholar] [CrossRef]
  2. Zamorano, J.L.; Lancellotti, P.; Rodriguez Muñoz, D.; Aboyans, V.; Asteggiano, R.; Galderisi, M.; et al. ESC Scientific Document Group 2016 ESC Position Paper on cancer treatments cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments cardiovascular toxicity of the European Society of Cardiology (ESC). Eur. Heart J. 2016, 37, 2768–2801. [Google Scholar]
  3. Cardinale, D.; Colombo, A.; Bacchiani, G.; Tedeschi, I.; Meroni, C.A.; Veglia, F.; et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015, 131, 1981–1988. [Google Scholar] [CrossRef]
  4. Darby, S.C.; Ewertz, M.; McGale, P.; Bennet, A.M.; Blom-Goldman, U.; Brønnum, D.; et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 2013, 368, 987–998. [Google Scholar] [CrossRef]
  5. Koelwyn, G.J.; Newman, A.A.; Afonso, M.S.; van Solingen, C.; Corr, E.M.; Brown, E.J.; et al. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nat. Med. 2020, 26, 1452–1458. [Google Scholar] [CrossRef]
  6. Korde, L.A.; Somerfield, M.R.; Carey, L.A.; Crews, J.R.; Denduluri, N.; Hwang, E.S.; et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J. Clin. Oncol. 2021, 39, 1485–1505. [Google Scholar] [CrossRef] [PubMed]
  7. Lyon, A.R.; Dent, S.; Stanway, S.; Earl, H.; Brezden-Masley, C.; Cohen-Solal, A.; et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur. J. Heart Fail. 2020, 22, 1945–1960. [Google Scholar] [PubMed]
  8. Ewer, M.S.; Ewer, S.M. Cardiotoxicity of anticancer treatments. Nat. Rev. Cardiol. 2015, 12, 547–558. [Google Scholar] [CrossRef]
  9. Zhang, S.; Liu, X.; Bawa-Khalfe, T.; Lu, L.S.; Lyu, Y.L.; Liu, L.F.; et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 2012, 18, 1639–1642. [Google Scholar] [CrossRef]
  10. Neilan, T.G.; Coelho-Filho, O.R.; Pena-Herrera, D.; Shah, R.V.; Jerosch-Herold, M.; Francis, S.A.; et al. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am. J. Cardiol. 2012, 110, 1679–1686. [Google Scholar] [CrossRef] [PubMed]
  11. Willis, M.S.; Parry, T.L.; Brown, D.I.; Mota, R.I.; Huang, W.; Beak, J.Y.; et al. Doxorubicin Exposure Causes Subacute Cardiac Atrophy Dependent on the Striated Muscle-Specific Ubiquitin Ligase MuRF1. Circ. Heart Fail. 2019, 12, e005234. [Google Scholar] [CrossRef]
  12. Swain, S.M.; Whaley, F.S.; Ewer, M.S. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003, 97, 2869–2879. [Google Scholar]
  13. Vejpongsa, P.; Yeh, E.T. Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities. J. Am. Coll. Cardiol. 2014, 64, 938–945. [Google Scholar]
  14. Cardinale, D.; Colombo, A.; Lamantia, G.; Colombo, N.; Civelli, M.; De Giacomi, G.; et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. J. Am. Coll. Cardiol. 2010, 55, 213–220. [Google Scholar] [CrossRef] [PubMed]
  15. Lyon, A.R.; López-Fernández, T.; Couch, L.S.; Asteggiano, R.; Aznar, M.C.; Bergler-Klein, J.; et al. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur. Heart J. 2022, 43, 4229–4361. [Google Scholar] [PubMed]
  16. Herrmann, J.; Lenihan, D.; Armenian, S.; Barac, A.; Blaes, A.; Cardinale, D.; et al. Defining cardiovascular toxicities of cancer therapies: An International Cardio-Oncology Society (IC-OS) consensus statement. Eur. Heart J. 2022, 43, 280–299. [Google Scholar] [CrossRef]
  17. Pudil, R.; Mueller, C.; Čelutkienė, J.; Henriksen, P.A.; Lenihan, D.; Dent, S.; et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: A position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur. J. Heart Fail. 2020, 22, 1966–1983. [Google Scholar] [CrossRef]
  18. Tiersten, A.; Wo, J.; Jacobson, C.; Weitzman, A.; Horwich, T.; Hesdorffer, C.; et al. Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer. Breast 2004, 13, 341–346. [Google Scholar]
  19. Veal, G.J.; Cole, M.; Chinnaswamy, G.; Sludden, J.; Jamieson, D.; Errington, J.; et al. Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma. Eur. J. Cancer 2016, 55, 56–64. [Google Scholar] [CrossRef]
  20. Braverman, A.C.; Antin, J.H.; Plappert, M.T.; Cook, E.F.; Lee, R.T. Cyclophosphamide cardiotoxicity in bone marrow transplantation: A prospective evaluation of new dosing regimens. J. Clin. Oncol. 1991, 9, 1215–1223. [Google Scholar] [CrossRef] [PubMed]
  21. Harbeck, N.; Gluz, O. Neoadjuvant therapy for triple negative and HER2-positive early breast cancer. Breast 2017, 34 (Suppl. 1), S99–S103. [Google Scholar] [CrossRef]
  22. Nakatsukasa, K.; Koyama, H.; Oouchi, Y.; Imanishi, S.; Mizuta, N.; Sakaguchi, K.; et al. Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer. Breast Cancer 2017, 24, 63–68. [Google Scholar] [CrossRef] [PubMed]
  23. Weaver, B.A.; Cleveland, D.W. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell. 2005, 8, 7–12. [Google Scholar] [CrossRef]
  24. Mackey, J.R.; Martin, M.; Pienkowski, T.; Rolski, J.; Guastalla, J.P.; Sami, A.; et al. TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013, 14, 72–80. [Google Scholar] [CrossRef]
  25. Holmes, F.A.; Rowinsky, E.K. Pharmacokinetic profiles of doxorubicin in combination with taxanes. Semin. Oncol. 2001, 28 (Suppl. 12), 8–14. [Google Scholar] [CrossRef]
  26. Salvatorelli, E.; Menna, P.; Cascegna, S.; Liberi, G.; Calafiore, A.M.; Gianni, L.; et al. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J. Pharmacol. Exp. Ther. 2006, 318, 424–433. [Google Scholar] [CrossRef]
  27. Suter, T.M.; Procter, M.; van Veldhuisen, D.J.; Muscholl, M.; Bergh, J.; Carlomagno, C.; et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J. Clin. Oncol. 2007, 25, 3859–3865. [Google Scholar] [CrossRef]
  28. Mehta, L.S.; Watson, K.E.; Barac, A.; Beckie, T.M.; Bittner, V.; Cruz-Flores, S.; et al. American Heart Association Cardiovascular Disease in Women and special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Cara and Outcomes Research. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation 2018, 137, e30–e66. [Google Scholar] [PubMed]
  29. Ewer, M.S.; Lippman, S.M. Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J. Clin. Oncol. 2005, 23, 2900–2902. [Google Scholar] [CrossRef] [PubMed]
  30. Haegler-Laube, E.S.; Rhyner, D.; Scheler, E.; Poku, N.K.; Rossi, V.A.; Rothschild, S.I.; et al. Swiss Cardio-Oncology Booklet. 2022. Available online: https://www.heartfailure.ch/images/richtlinien/KONK-Booklet_Final__Version_1.1_06.2022.pdf (accessed on 1 February 2023).
  31. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344, 783–792. [Google Scholar] [CrossRef]
  32. Higgins, A.Y.; O’Halloran, T.D.; Chang, J.D. Chemotherapy-induced cardiomyopathy. Heart Fail. Rev. 2015, 20, 721–730. [Google Scholar] [CrossRef]
  33. Perez, E.A.; Suman, V.J.; Davidson, N.E.; Sledge, G.W.; Kaufman, P.A.; Hudis, C.A.; et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J. Clin. Oncol. 2008, 26, 1231–1238. [Google Scholar] [CrossRef]
  34. Armenian, S.H.; Lacchetti, C.; Barac, A.; Carver, J.; Constine, L.S.; Denduluri, N.; et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2017, 35, 893–911. [Google Scholar] [CrossRef]
  35. Lewinter, C.; Nielsen, T.H.; Edfors, L.R.; Linde, C.; Bland, J.M.; LeWinter, M.; et al. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. Eur. Heart J. 2022, 43, 2562–2569. [Google Scholar] [CrossRef] [PubMed]
  36. Modi, S.; Saura, C.; Yamashita, T.; Park, Y.H.; Kim, S.B.; Tamura, K.; et al. DESTINY-Breast04 Trial Investigators Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer, N. Engl. J. Med. 2020, 382, 610–621. [Google Scholar] [CrossRef]
  37. Modi, S.; Jacot, W.; Yamashita, T.; Sohn, J.; Vidal, M.; Tokunaga, E.; et al. DESTINY-Breast04 Trial Investigators Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer, N. Engl. J. Med. 2022, 387, 9–20. [Google Scholar] [CrossRef]
  38. von Minckwitz, G.; Huang, C.S.; Mano, M.S.; Loibl, S.; Mamounas, E.P.; Untch, M.; et al. KATHERINE Investigators Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast, Cancer. N. Engl. J. Med. 2019, 380, 617–628. [Google Scholar] [CrossRef]
  39. Bardia, A.; Hurvitz, S.A.; Tolaney, S.M.; Loirat, D.; Punie, K.; Oliveira, M.; et al. ASCENT Clinical Trial Investigators Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer, N. Engl. J. Med. 2021, 384, 1529–1541. [Google Scholar] [CrossRef] [PubMed]
  40. Saiki, H.; Petersen, I.A.; Scott, C.G.; Bailey, K.R.; Dunlay, S.M.; Finley, R.R.; et al. Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer. Circulation 2017, 135, 1388–1396. [Google Scholar] [CrossRef]
  41. Mandraffino, G.; Dalbeni, A.; Paunovic, N.; Mormina, E.M.; Imbalzano, E. Radiation-induced heart and vessel atherosclerosis disease. Int. J. Cardiol. 2014, 172, 505–506. [Google Scholar] [CrossRef]
  42. Giordano, S.H.; Kuo, Y.F.; Freeman, J.L.; Buchholz, T.A.; Hortobagyi, G.N.; Goodwin, J.S. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J. Natl. Cancer Inst. 2005, 97, 419–424. [Google Scholar] [CrossRef]
  43. Gujral, D.M.; Lloyd, G.; Bhattacharyya, S. Radiation-induced valvular heart disease. Heart 2016, 102, 269–276. [Google Scholar] [CrossRef]
  44. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005, 365, 1687–1717. [Google Scholar] [CrossRef] [PubMed]
  45. Burstein, H.J.; Lacchetti, C.; Anderson, H.; Buchholz, T.A.; Davidson, N.E.; Gelmon, K.A.; et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J. Clin. Oncol. 2019, 37, 423–438. [Google Scholar] [CrossRef]
  46. Manson, J.E.; Hsia, J.; Johnson, K.C.; Rossouw, J.E.; Assaf, A.R.; Lasser, N.L.; et al. Women’s Health Initiative Investigators Estrogen plus progestin the risk of coronary heart disease. N. Engl. J. Med. 2003, 349, 523–534. [Google Scholar] [CrossRef] [PubMed]
  47. Bernhard, J.; Luo, W.; Ribi, K.; Colleoni, M.; Burstein, H.J.; Tondini, C.; et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): A combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015, 16, 848–858. [Google Scholar] [CrossRef]
  48. Del Mastro, L.; Ceppi, M.; Poggio, F.; Bighin, C.; Peccatori, F.; Demeestere, I.; et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. Cancer Treat. Rev. 2014, 40, 675–683. [Google Scholar] [CrossRef]
  49. Fabian, C.J. The what, why and how of aromatase inhibitors: Hormonal agents for treatment and prevention of breast cancer. Int. J. Clin. Pract. 2007, 61, 2051–2063. [Google Scholar] [CrossRef]
  50. Masuda, N.; Sagara, Y.; Kinoshita, T.; Iwata, H.; Nakamura, S.; Yanagita, Y.; et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): A double-blind, randomised phase 3 trial. Lancet Oncol. 2012, 13, 345–352. [Google Scholar] [CrossRef] [PubMed]
  51. Amir, E.; Seruga, B.; Niraula, S.; Carlsson, L.; Ocaña, A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis. J. Natl. Cancer Inst. 2011, 103, 1299–1309. [Google Scholar] [CrossRef]
  52. Thürlimann, B.; Keshaviah, A.; Coates, A.S.; Mouridsen, H.; Mauriac, L.; et al. Breast International Group (BIG) 1-98 Collaborative Group Acomparison of letrozole tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 2005, 353, 2747–2757. [Google Scholar]
  53. Goss, P.E.; Ingle, J.N.; Martino, S.; Robert, N.J.; Muss, H.B.; Piccart, M.J.; et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 2003, 349, 1793–1802. [Google Scholar] [CrossRef]
  54. Cuppone, F.; Bria, E.; Verma, S.; Pritchard, K.I.; Gandhi, S.; Carlini, P.; et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 2008, 112, 260–267. [Google Scholar]
  55. Gao, J.J.; Cheng, J.; Bloomquist, E.; Sanchez, J.; Wedam, S.B.; Singh, H.; et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: A US Food and Drug Administration pooled analysis. Lancet Oncol. 2020, 21, 250–260. [Google Scholar] [CrossRef]
  56. Tripathy, D.; Im, S.A.; Colleoni, M.; Franke, F.; Bardia, A.; Harbeck, N.; et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. Lancet Oncol. 2018, 19, 904–915. [Google Scholar] [CrossRef]
  57. Vranic, S.; Cyprian, F.S.; Gatalica, Z.; Palazzo, J. PD-L1 status in breast cancer: Current view and perspectives. Semin Cancer Biol. 2021, 72, 146–154. [Google Scholar] [CrossRef]
  58. Schmid, P.; Cortes, J.; Dent, R.; Pusztai, L.; McArthur, H.; Kümmel, S.; et al. KEYNOTE-552 Investigators Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N. Engl. J. Med. 2022, 386, 556–567. [Google Scholar] [CrossRef]
  59. Cortes, J.; Cescon, D.W.; Rugo, H.S.; Nowecki, Z.; Im, S.A.; Yusof, M.M.; et al. KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020, 396, 1817–1828. [Google Scholar] [PubMed]
  60. Lyon, A.R.; Yousaf, N.; Battisti, N.M.; Moslehi, J.; Larkin, J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018, 19, e447–e458. [Google Scholar] [CrossRef] [PubMed]
  61. Brahmer, J.R.; Abu-Sbeih, H.; Ascierto, P.A.; Brufsky, J.; Cappelli, L.C.; Cortazar, F.B.; et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021, 9, e002435. [Google Scholar] [CrossRef] [PubMed]
  62. Paterson, D.I.; Wiebe, N.; Cheung, W.Y.; Mackey, J.R.; Pituskin, E.; Reiman, A.; et al. Incident Cardiovascular Disease Among Adults With Cancer: A Population-Based Cohort Study. JACC Cardiooncol. 2022, 4, 85–94. [Google Scholar] [CrossRef] [PubMed]
  63. Strongman, H.; Gadd, S.; Matthews, A.A.; Mansfield, K.E.; Stanway, S.; Lyon, A.R.; et al. Does Cardiovascular Mortality Overtake Cancer Mortality During Cancer Survivorship?: An English Retrospective Cohort Study. JACC Cardiooncol. 2022, 4, 113–123. [Google Scholar] [CrossRef]
  64. Ramin, C.; Schaeffer, M.L.; Zheng, Z.; Connor, A.E.; Hoffman-Bolton, J.; Lau, B.; et al. All-Cause and Cardiovascular Disease Mortality Among Breast Cancer Survivors in CLUE II, a Long-Standing Community-Based Cohort. J. Natl. Cancer Inst. 2021, 113, 137–145. [Google Scholar] [CrossRef] [PubMed]
  65. Bradshaw, P.T.; Stevens, J.; Khankari, N.; Teitelbaum, S.L.; Neugut, A.I.; Gammon, M.D. Cardiovascular Disease Mortality Among Breast Cancer Survivors. Epidemiology 2016, 27, 6–13. [Google Scholar] [CrossRef]
  66. Reding, K.W.; Cheng, R.K.; Vasbinder, A.; Ray, R.M.; Barac, A.; Eaton, C.B.; et al. Lifestyle and Cardiovascular Risk Factors Associated With Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors. JACC Cardiooncol. 2022, 4, 53–65. [Google Scholar] [CrossRef]
  67. Greenlee, H.; Iribarren, C.; Rana, J.S.; Cheng, R.; Nguyen-Huynh, M.; Rillamas-Sun, E.; et al. Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. J. Clin. Oncol. 2022, 40, 1647–1658. [Google Scholar] [CrossRef]
  68. Cho, H.; Lee, S.; Sim, S.H.; Park, I.H.; Lee, K.S.; Kwak, M.H.; et al. Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients. Breast Cancer Res. Treat 2020, 182, 333–343. [Google Scholar] [CrossRef]
  69. Abdel-Qadir, H.; Thavendiranathan, P.; Austin, P.C.; Lee, D.S.; Amir, E.; Tu, J.V.; et al. The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study. J. Natl. Cancer Inst. 2019, 111, 854–862. [Google Scholar] [CrossRef]
  70. Guha, A.; Fradley, M.G.; Dent, S.F.; Weintraub, N.L.; Lustberg, M.B.; Alonso, A.; et al. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: A SEER-Medicare analysis. Eur. Heart J. 2022, 43, 300–312. [Google Scholar] [CrossRef]
  71. Koric, A.; Chang, C.P.; Mark, B.; Rowe, K.; Snyder, J.; Dodson, M.; et al. Cardiovascular disease risk in long-term breast cancer survivors: A population-based cohort study. Cancer 2022, 128, 2826–2835. [Google Scholar] [CrossRef] [PubMed]
  72. Zheng, J.S.; Hu, X.J.; Zhao, Y.M.; Yang, J.; Li, D. Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: Meta-analysis of data from 21 independent prospective cohort studies. BMJ 2013, 346, f3706. [Google Scholar] [CrossRef]
  73. Martin, L.J.; Li, Q.; Melnichouk, O.; Greenberg, C.; Minkin, S.; Hislop, G.; et al. A randomized trial of dietary intervention for breast cancer prevention. Cancer Res. 2011, 71, 123–133. [Google Scholar] [CrossRef]
  74. Ronksley, P.E.; Brien, S.E.; Turner, B.J.; Mukamal, K.J.; Ghali, W.A. Association of alcohol consumption with selected cardiovascular disease outcomes: A systematic review and meta-analysis. BMJ.
  75. Suzuki, R.; Orsini, N.; Mignone, L.; Saji, S.; Wolk, A. Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis of epidemiological studies. Int. J. Cancer 2008, 122, 1832–1841. [Google Scholar] [PubMed]
  76. Visseren, F.L.; Mach, F.; Smulders, Y.M.; Carballo, D.; Koskinas, K.C.; Bäck, M.; et al. ESC National Cardiac Societies; ESC Scientific Document Group 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021, 42, 3227–3337. [Google Scholar] [CrossRef]
  77. Lahart, I.M.; Metsios, G.S.; Nevill, A.M.; Carmichael, A.R. Physical activity, risk of death and recurrence in breast cancer survivors: A systematic review and meta-analysis of epidemiological studies. Acta Oncol. 2015, 54, 635–654. [Google Scholar] [CrossRef] [PubMed]
  78. Pizot, C.; Boniol, M.; Mullie, P.; Koechlin, A.; Boniol, M.; Boyle, P.; et al. Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies. Eur. J. Cancer 2016, 52, 138–154. [Google Scholar] [CrossRef]
  79. Spei, M.E.; Samoli, E.; Bravi, F.; La Vecchia, C.; Bamia, C.; Benetou, V. Physical activity in breast cancer survivors: A systematic review and meta-analysis on overall and breast cancer survival. Breast 2019, 44, 144–152. [Google Scholar] [CrossRef]
  80. Friedenreich, C.M.; Ryder-Burbidge, C.; McNeil, J. Physical activity, obesity and sedentary behavior in cancer etiology: Epidemiologic evidence and biologic mechanisms. Mol. Oncol. 2021, 15, 790–800. [Google Scholar]
  81. Keum, N.; Greenwood, D.C.; Lee, D.H.; Kim, R.; Aune, D.; Ju, W.; et al. Adult weight gain and adiposity-related cancers: A dose-response meta-analysis of prospective observational studies. J. Natl. Cancer Inst. 2015, 107, dju428. [Google Scholar] [CrossRef]
  82. Rosner, B.; Eliassen, A.H.; Toriola, A.T.; Hankinson, S.E.; Willett, W.C.; Natarajan, L.; et al. Short-term weight gain and breast cancer risk by hormone receptor classification among pre- and postmenopausal women. Breast Cancer Res. Treat 2015, 150, 643–653. [Google Scholar]
  83. Macacu, A.; Autier, P.; Boniol, M.; Boyle, P. Active and passive smoking and risk of breast cancer: A meta-analysis. Breast Cancer Res. Treat 2015, 154, 213–224. [Google Scholar] [CrossRef]
  84. Jones, M.E.; Schoemaker, M.J.; Wright, L.B.; Ashworth, A.; Swerdlow, A.J. Smoking and risk of breast cancer in the Generations Study cohort. Breast Cancer Res. 2017, 19, 118. [Google Scholar] [CrossRef]
  85. Berrandou, T.; Mulot, C.; Cordina-Duverger, E.; Arveux, P.; Laurent-Puig, P.; Truong, T.; et al. Association of breast cancer risk with polymorphisms in genes involved in the metabolism of xenobiotics and interaction with tobacco smoking: A gene-set analysis. Int. J. Cancer 2019, 144, 1896–1908. [Google Scholar] [CrossRef]
  86. Libby, P.; Nahrendorf, M.; Swirski, F.K. Leukocytes Link Local and Systemic Inflammation in Ischemic Cardiovascular Disease: An Expanded “Cardiovascular Continuum”. J. Am. Coll. Cardiol. 2016, 67, 1091–1103. [Google Scholar] [CrossRef]
  87. Engblom, C.; Pfirschke, C.; Pittet, M.J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 2016, 16, 447–462. [Google Scholar] [CrossRef] [PubMed]
  88. Hasin, T.; Gerber, Y.; Weston, S.A.; Jiang, R.; Killian, J.M.; Manemann, S.M.; et al. Heart Failure After Myocardial Infarction Is Associated With Increased Risk of Cancer. J. Am. Coll. Cardiol. 2016, 68, 265–271. [Google Scholar] [CrossRef]
  89. Hasin, T.; Gerber, Y.; McNallan, S.M.; Weston, S.A.; Kushwaha, S.S.; Nelson, T.J.; et al. Patients with heart failure have an increased risk of incident cancer. J. Am. Coll. Cardiol. 2013, 62, 881–886. [Google Scholar] [CrossRef]
  90. Meijers, W.C.; Maglione, M.; Bakker, S.J.; Oberhuber, R.; Kieneker, L.M.; de Jong, S.; et al. Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation 2018, 138, 678–691. [Google Scholar] [CrossRef]
  91. Ridker, P.M.; MacFadyen, J.G.; Thuren, T.; Everett, B.M.; Libby, P.; Glynn, R.J.; et al. CANTOS Trial Group. Effect of interleukin-1b inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017, 390, 1833–1842. [Google Scholar] [CrossRef] [PubMed]
  92. Pavo, N.; Raderer, M.; Hülsmann, M.; Neuhold, S.; Adlbrecht, C.; Strunk, G.; et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart 2015, 101, 1874–1880. [Google Scholar] [CrossRef] [PubMed]
  93. Stack, J.P.; Moslehi, J.; Sayed, N.; Wu, J.C. Cancer therapy-induced cardiomyopathy: Can human induced pluripotent stem cell modelling help prevent it? Eur. Heart J. 2019, 40, 1764–1770. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Overview of the different types of breast cancer and their therapies. Simplified breast cancer-related risk stratification and related, most used therapies. AI: Aromatase inhibitor; dd: dose-dense; GnRH: Gonadotropin-releasing hormone agonists; HER2: Human epidermal growth factor receptor 2; HR: Hormone receptor; pCR: Pathological complete remission; TDM1: Trastuzumab emtansine.
Figure 1. Overview of the different types of breast cancer and their therapies. Simplified breast cancer-related risk stratification and related, most used therapies. AI: Aromatase inhibitor; dd: dose-dense; GnRH: Gonadotropin-releasing hormone agonists; HER2: Human epidermal growth factor receptor 2; HR: Hormone receptor; pCR: Pathological complete remission; TDM1: Trastuzumab emtansine.
Cardiovascmed 26 00100 g001
Figure 2. Cardiotoxicity of the most important therapies against breast cancer. ICIs: Immune checkpoint inhibitors; LVEF: Left ventricular ejection fraction; TKI: Tyrosine kinase inhibitors; VEGF/R: Vascular endothelial growth factor/receptor.
Figure 2. Cardiotoxicity of the most important therapies against breast cancer. ICIs: Immune checkpoint inhibitors; LVEF: Left ventricular ejection fraction; TKI: Tyrosine kinase inhibitors; VEGF/R: Vascular endothelial growth factor/receptor.
Cardiovascmed 26 00100 g002
Figure 3. Shared risk factors and disease interactions between breast cancer and cardiovascular disease. The Figure was partly generated using Servier Medical Art, provided by Servier, licensed under a Creative Commons Attribution 3.0 unported license.
Figure 3. Shared risk factors and disease interactions between breast cancer and cardiovascular disease. The Figure was partly generated using Servier Medical Art, provided by Servier, licensed under a Creative Commons Attribution 3.0 unported license.
Cardiovascmed 26 00100 g003

Share and Cite

MDPI and ACS Style

Rossi, V.A.; Oseledchyk, A.; Kuster, G.M. Breast Cancer and Cardiovascular Rsk. Cardiovasc. Med. 2023, 26, 100. https://doi.org/10.4414/cvm.2023.02275

AMA Style

Rossi VA, Oseledchyk A, Kuster GM. Breast Cancer and Cardiovascular Rsk. Cardiovascular Medicine. 2023; 26(3):100. https://doi.org/10.4414/cvm.2023.02275

Chicago/Turabian Style

Rossi, Valentina A., Anton Oseledchyk, and Gabriela M. Kuster. 2023. "Breast Cancer and Cardiovascular Rsk" Cardiovascular Medicine 26, no. 3: 100. https://doi.org/10.4414/cvm.2023.02275

APA Style

Rossi, V. A., Oseledchyk, A., & Kuster, G. M. (2023). Breast Cancer and Cardiovascular Rsk. Cardiovascular Medicine, 26(3), 100. https://doi.org/10.4414/cvm.2023.02275

Article Metrics

Back to TopTop